series-c-plus
Stage
2007
Founded
3
Investors
About
Immunic is a late-stage biotechnology company developing orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, including multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis.
Explore Immunic AG's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.